(Q44292349)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

1 December 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

RETRACTED: Inhibition of PKM2 sensitizes triple-negative breast cancer cells to doxorubicin (English)

1 reference

triple-negative breast cancer

1 December 2017

main subject

1 reference

Feng Wang

1

1 reference

1 December 2017

Yong Yang

series ordinal

2

1 reference

1 December 2017

language of work or name

English

0 references

publication date

29 October 2014

1 reference

Biochemical and Biophysical Research Communications

1 December 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

1 December 2017

volume

454

1 reference

1 December 2017

issue

3

1 reference

1 December 2017

page(s)

465-470

1 reference

RETRACTED: Quercetin suppresses insulin receptor signaling through inhibition of the insulin ligand-receptor binding and therefore impairs cancer cell proliferation

1 December 2017

cites work

2 references

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1016/J.BBRC.2014.09.039

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Pyruvate kinase M2 is a phosphotyrosine-binding protein

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

RETRACTED: Identification of an antitumor immune response of polyhistidine through a toll-like receptor 4-dependent manner.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Triple-negative breast cancer: therapeutic options

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Triple-negative breast cancer: role of specific chemotherapy agents

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Targeting triple-negative breast cancer: optimising therapeutic outcomes

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

The development and characterization of a glutathione-sensitive cross-linked polyethylenimine gene vector.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Histological and molecular types of breast cancer: is there a unifying taxonomy?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Locoregional treatment outcomes after multimodality management of inflammatory breast cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Serine is a natural ligand and allosteric activator of pyruvate kinase M2

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Polyethylenimine-based non-viral gene delivery systems

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Targeted therapy for triple-negative breast cancer: where are we?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BBRC.2014.10.109

Identifiers

DOI

10.1016/J.BBRC.2014.10.109

1 reference

1 December 2017

1 reference